<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804934</url>
  </required_header>
  <id_info>
    <org_study_id>F4421S</org_study_id>
    <nct_id>NCT00804934</nct_id>
  </id_info>
  <brief_title>Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis</brief_title>
  <official_title>Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Institute of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Institute of Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether people who have received intermittent
      anti-VEGF therapy have an improvement in vision after being switched to monthly injections of
      Lucentis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine mean change in visual acuity at 6 and 12 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Mean change in visual acuity at 6 and 12 months</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Wet AMD</condition>
  <arm_group>
    <arm_group_label>0</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>0.5mg Lucentis every four months</description>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age greater then and equal 50 years

          -  Patients with active neovascular AMD

          -  Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or
             ranibizumab) in the last 24 months

          -  If the patient has bilateral disease and qualifies for the study, both eyes may be
             included

        Exclusion Criteria:

          -  Subjects who meet any of the following criteria will be excluded from this study:

          -  Pregnancy or lactation

          -  Premenopausal women not using adequate contraception.

          -  Participation in another simultaneous medical investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra L Shimabukuro, RN</last_name>
    <role>Study Chair</role>
    <affiliation>Retina Institute of Hawaii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Institute of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>May 24, 2012</last_update_submitted>
  <last_update_submitted_qc>May 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

